Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the effects of GLP-1 on accumulation of monocytes/macrophages on the vascular wall, one of the earliest steps in atherosclerogenesis. RESEARCH DESIGN AND METHODS: After continuous infusion of low (300 pmol · kg−1 · day−1) or high (24 nmol · kg−1 · day−1) dose of exendin-4 in C57BL/6 or apolipoprotein E–deficient mice (apoE−/−), we evaluated monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve. The effects of exendin-4 were investigated in mouse macrophages and human monocytes. RESULTS: Treatment with exendin-4 significantly inhibited monocytic adhesion in the aortas of C57BL/6 mice without affecting metabolic parameters. In apoE−/− mice, the same treatment reduced monocyte adhesion to the endothelium and suppressed atherosclerogenesis. In vitro treatment of mouse macrophages with exendin-4 suppressed lipopolysaccharide-induced mRNA expression of tumor necrosis factor-α and monocyte chemoattractant protein-1, and suppressed nuclear translocation of p65, a component of nuclear factor-κB. This effect was reversed by either MDL-12330A, a cAMP inhibitor or PKI14-22, a protein kinase A–specific inhibitor. In human monocytes, exendin-4 reduced the expression of CD11b. CONCLUSIONS: Our data suggested that GLP-1 receptor agonists reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages, and that this effect may contribute to the attenuation of atherosclerotic lesion by exendin-4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17]”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“Within the cardiovascular system, GLP-1 receptors are expressed on endothelial cells, monocytes, macrophages, and vascular smooth muscle cells (VSMCs) [9].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Similar to lung and pancreatic -cells (24), mice peritoneal macrophages and vascular smooth muscle cells abundantly expressed GLP-1 receptor protein, and the expression level was higher than in freshly isolated endothelial cells.”
ResultGu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., & Rollins, B. J. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80139-2 · Cited by 1,575 · cited 1×
“Both TNF- – and MCP-1–deficient mice have significantly reduced atherosclerotic lesions (29,30).”
BackgroundA major role for VCAM-1, but not ICAM-1, in early atherosclerosis
Cybulsky, M. I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., Davis, V., Gutierrez-Ramos, J.-C., Connelly, P. W., & Milstone, D. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11871 · Cited by 1,217 · cited 2×
“The adhesion of circulating monocytes to the intimal endothelial cells is thought to be one of the earliest events in the complex pathological process of atherosclerogenesis (14; 15).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“In vascular endothelial cells, GLP-1 stimulates NO production, which may explain the vasodilatory effects in mesenteric arteries (11) and pulmonary artery rings (12).”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundEbato, C., Uchida, T., Arakawa, M., Komatsu, M., Ueno, T., Komiya, K., Azuma, K., Hirose, T., Tanaka, K., Kominami, E., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.009 · Cited by 774 · cited 2×
“) or rabbit anti–glyceraldehyde-3-phosphate dehydrogenase antibody (Cell Signaling Technology, Beverly, MA) as described previously (16).”
BackgroundMethodSelf-citationNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
Background
Cited by
Items 101–200 of 560
Nogi, Y., Nagashima, M., Terasaki, M., Nohtomi, K., Watanabe, T., & Hirano, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035683 · Cited by 96
Tate, M., Robinson, E., Green, B. D., McDermott, B. J., & Grieve, D. J. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-015-0518-1 · Cited by 96
Favaro, E., Granata, R., Miceli, I., Baragli, A., Settanni, F., Perin, P. C., Ghigo, E., Camussi, G., & Zanone, M. M. (2012) · Diabetologia · doi:10.1007/s00125-011-2423-y · Cited by 97
Wu, H.-Y., Tang, X.-Q., Mao, X.-F., & Wang, Y.-X. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1799-17.2017 · Cited by 87
“…microglia, but not in astrocytes and neurons, similar to the previous studies in which exenatide stimulated IL-10 and IL-4 expression in human monocytes/macrophage and regulatory T cells (Ayasolla et al., 2004; Xue et al., 2008; Arakawa et al., 2010; McClean et al., 2011; Bułdak et al., 2016).”
BackgroundResultShi, L., Ji, Y., Jiang, X., Zhou, L., Xu, Y., Li, Y., Jiang, W., Meng, P., & Liu, X. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0177-4 · Cited by 91
Coming full circle in diabetes mellitus: from complications to initiation
Harcourt, B. E., Penfold, S. A., & Forbes, J. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.236 · Cited by 97
Inoue, K., Maeda, N., Kashine, S., Fujishima, Y., Kozawa, J., Hiuge-Shimizu, A., Okita, K., Imagawa, A., Funahashi, T., & Shimomura, I. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-109 · Cited by 89
GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells
Li, Q., Lin, Y., Wang, S., Zhang, L., & Guo, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-06712-z · Cited by 87
Patel, R., Wadid, M., Makwana, B., Kumar, A., Khadke, S., Bhatti, A., Banker, A., Husami, Z., Labib, S., Venesy, D., et al. (2024) · JACC: Heart Failure · doi:10.1016/j.jchf.2024.07.006 · Cited by 72
Matheeussen, V., Waumans, Y., Martinet, W., Goethem, S. V., der Veken, P. V., Scharpé, S., Augustyns, K., Meyer, G. R. Y. D., & Meester, I. D. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0350-4 · Cited by 90
Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis
Bruen, R., Curley, S., Kajani, S., Crean, D., O’Reilly, M. E., Lucitt, M. B., Godson, C. G., McGillicuddy, F. C., & Belton, O. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0626-3 · Cited by 81
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
Davidson, M. H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.046 · Cited by 88
Mitchell, P. D., Salter, B. M., Oliveria, J. P., El‐Gammal, A., Tworek, D., Smith, S. G., Sehmi, R., Gauvreau, G. M., Butler, M., & O'Byrne, P. M. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12860 · Cited by 78
“Lipopolysaccharide (LPS)induced macrophage activation in vitro and TNF-α expression was significantly reduced following treatment with the GLP-1 analog through inhibition of the PKA/NF-κB signaling pathway (22).”
BackgroundMethodBułdak, Ł., Machnik, G., Bułdak, R. J., Łabuzek, K., Bołdys, A., Belowski, D., Basiak, M., & Okopień, B. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.10.008 · Cited by 84
Kaneto, H., Kimura, T., Obata, A., Shimoda, M., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052596 · Cited by 90
The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
Dietrich, N., Kolibabka, M., Busch, S., Bugert, P., Kaiser, U., Lin, J., Fleming, T. H., Morcos, M., Klein, T., Schlotterer, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167853 · Cited by 84
GLP‐1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
Lorber, D. (2013) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12000 · Cited by 77
AlZaim, I., Hammoud, S. H., Al-Koussa, H., Ghazi, A., Eid, A. H., & El-Yazbi, A. F. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.602088 · Cited by 73
Burgmaier, M., Liberman, A., Möllmann, J., Kahles, F., Reith, S., Lebherz, C., Marx, N., & Lehrke, M. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.08.033 · Cited by 82
Monocytes and macrophages as protagonists in vascular complications of diabetes
Kanter, J. E., Hsu, C.-C., & Bornfeldt, K. E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00010 · Cited by 76
“Nevertheless, exendin-4 (a GLP-1 receptor agonist) has been shown to reduce atherosclerosis andmonocyte adhesion to aortas as well as inflammatory gene expression in macrophages in mice, likely by increasing cAMP levels in these cells (167).”
BackgroundDipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
Joo, K. W., Kim, S., Ahn, S. Y., Chin, H. J., Chae, D., Lee, J., Han, J. S., & Na, K. Y. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-98 · Cited by 82
“The anti-inflammatory effect of GLP-1R activation was also reported in the animal model of atherosclerosis [41].”
BackgroundZhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., & Rajagopalan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/606031 · Cited by 72
“Continuous infusion of exendin-4 for 4 weeks reduced neointimal formation [108], foam cell formation [109], and atherosclerotic lesion size [109, 110].”
BackgroundErdogdu, Ö., Eriksson, L., Xu, H., Sjöholm, Å., Zhang, Q., & Nyström, T. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0166 · Cited by 75
“Exendin-4 reduces macrophage adhesion to the endothelium, an early step in the formation of atherosclerotic plaques and endothelial dysfunction (Arakawa et al. 2010).”
BackgroundPeng, W., Zhou, R., Sun, Z.-F., Long, J.-W., & Gong, Y.-Q. (2022) · Aging and disease · doi:10.14336/ad.2021.0928 · Cited by 71
Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
“Within the cardiovascular system, GLP-1 receptors are expressed on endothelial cells, monocytes, macrophages, and vascular smooth muscle cells (VSMCs) [9].”
BackgroundProper Management of People with Obesity during the COVID-19 Pandemic
Lim, S. K., Shin, S. M., Nam, G. E., Jung, C. H., & Koo, B. K. (2020) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20056 · Cited by 78
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
“The figure illustrates GLP-1(7-36) amide.”
Sancar-Bas, S., Gezginci-Oktayoglu, S., & Bolkent, S. (2015) · Growth Factors · doi:10.3109/08977194.2015.1125349 · Cited by 71
“Exendin-4 shares several useful biological properties with GLP-1 and beside glucoregulatory actions as GLP-1 has; it has been reported exendin-4 has antiinflammatory effects in the atherosclerosis and retinopathy (Arakawa et al., 2010; Dorecka et al., 2013).”
BackgroundRobinson, E., Cassidy, R. S., Tate, M., Zhao, Y., Lockhart, S., Calderwood, D., Church, R., McGahon, M. K., Brazil, D. P., McDermott, B. J., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0476-7 · Cited by 67
“Furthermore, complementary experiments in BMDM, which expressed the GLP-1R, found that exendin-4 differentially modulated basal levels of both resident and secreted macrophage response genes, which are known to contribute to tissue remodelling and repair [52, 53].”
BackgroundBifari, F., Manfrini, R., Dei Cas, M., Berra, C., Siano, M., Zuin, M., Paroni, R., & Folli, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 69
He, L., Wong, C. K., Cheung, K. K., Yau, H. C., Fu, A., Zhao, H., Leung, K. M., Kong, A. P., Wong, G. W., Chan, P. K., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12063 · Cited by 70
An Overview of Glycosylation and its Impact on Cardiovascular Health and Disease
Loaeza-Reyes, K. J., Zenteno, E., Rodríguez, A. M., Rosas, R. T., Argueta‐Figueroa, L., Salinas-Marín, R., Castillo-Real, L. M., Pina-Canseco, M. D. S., & Pérez-Cervera, Y. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.751637 · Cited by 76
“Specifically, exendin-4, a glucagon-like peptide 1 receptor agonist, has been shown to reduce atherosclerosis and monocyte adhesion to aortas, as well as the expression of the inflammatory gene in macrophages in mice, likely by increasing cAMP levels in these cells (Arakawa et al., 2010); therefore, glucagon-like pept…”
BackgroundBile acids at the cross-roads of gut microbiome–host cardiometabolic interactions
Ryan, P. M., Stanton, C., & Caplice, N. M. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0299-9 · Cited by 71
“…cardioprotective effects, in terms of inhibiting triglyceride-rich chylomicron formation [57, 58], attenuation of atherogenic plaque inflammation [59] and modulation of cardiomyocyte function [60, 61], the importance of bile acid-mediated GLP-1 secretion in the context of CVD has not yet been…”
Lim, S. K., Kim, K. M., & Nauck, M. A. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.01.011 · Cited by 76
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68
Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease
Steven, S., Münzel, T. F., & Daiber, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160818185 · Cited by 72
CHILTON, R. J., Wyatt, J., Nandish, S., OLIVEROS, R. A., & Lujan, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.004 · Cited by 72
Torres, G., Morales, P. E., García-Miguel, M., Norambuena-Soto, I., Cartes-Saavedra, B., Vidal-Peña, G., Moncada-Ruff, D., Sanhueza-Olivares, F., San Martín, A., & Chiong, M. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.01.013 · Cited by 67
“Exendin-4 and GLP-1 prevent the progression of atherosclerosis in apoE−/− mice, without major effects on metabolic parameters, and markedly reduced the accumulation of monocytes/macrophages in the vascular wall [43, 45].”
BackgroundVascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
“Similarly, a 28-day infusion of Ex-4 at low (300 pmol/kg/d) or high (24 nmol/kg/d) doses in 8-week-old Apoe / mice reduced the density of monocyte adhesion in the aorta, and the higher dose of Ex-4 reduced the atherosclerotic lesion area in the aortic sinus (94).”
BackgroundInfluentialGoncalves, E., & Bell, D. S. H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0420-6 · Cited by 61
Kahles, F., Liberman, A., Halim, C., Rau, M., Möllmann, J., Mertens, R. W., Rückbeil, M., Diepolder, I., Walla, B., Diebold, S., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.014 · Cited by 64
“For example, we and others found GLP-1 to reduce and stabilize atherosclerotic lesions in ApoE / mice by directly blocking monocyte migration and preventing inflammatory activation of monocytes/macrophages [4, 5].”
BackgroundSong, W., Zhang, C., Gou, L., He, L., Gong, Y.-Y., Qu, D. C., Zhao, L., Jin, N., Chan, T., Wang, L., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312316 · Cited by 71
GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease
Lebherz, C., Schlieper, G., Möllmann, J., Kahles, F., Schwarz, M., Brünsing, J., Dimkovic, N., Koch, A., Trautwein, C., Flöge, J., et al. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.03.010 · Cited by 65
Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
Roan, J.-N., Cheng, H.-N., Young, C., Lee, C.-J., Yeh, M.-L., Luo, C.-Y., Tsai, Y., & Lam, C. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2016.09.024 · Cited by 57
Gonçalves, A., Lin, C.-M., Muthusamy, A., Fontes-Ribeiro, C., Ambrósio, A. F., Abcouwer, S. F., Fernandes, R., & Antonetti, D. A. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-19006 · Cited by 64
“Treatment of isolated mouse macrophages with Ex-4 suppresses LPS-induced gene expression of TNF and CCL2 by a mechanism dependent on adenylate cyclase and PKA activation, and prevents nuclear translocation of p65.(26) Additionally, Ex-4 also attenuates high glucose–induced TNF and IL-1b expression and secretion by mac…”
BackgroundMolecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 66
Nozu, T., Miyagishi, S., Kumei, S., Nozu, R., Takakusaki, K., & Okumura, T. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13808 · Cited by 62
Chen, J., Wang, D., Wang, F., Shi, S., Chen, Y., Yang, B., Tang, Y., & Huang, C. (2017) · Peptides · doi:10.1016/j.peptides.2017.02.008 · Cited by 65
Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 56
Miyoshi, T., Nakamura, K., Yoshida, M., Miura, D., Oe, H., Akagi, S., Sugiyama, H., Akazawa, K., Yonezawa, T., Wada, J., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-43 · Cited by 63
“Glucagon-like peptide-1 (GLP-1 [7-35]) amide is an incretin hormone secreted mainly by the entero-endocrine cells of the intestine in response to the presence of nutrients [7].”
BackgroundZhao, L., Li, A. Q., Zhou, T. F., Zhang, M. Q., & Qin, X. M. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00151.2014 · Cited by 61
Ha, S. J., Kim, W., Woo, J. S., Kim, J. B., Kim, S. J., Kim, W.-S., Kim, M. K., Cheng, X. W., & Kim, K. S. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.222653 · Cited by 58
Bonfioli, G. B., Rodella, L., Metra, M., & Vizzardi, E. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10450-6 · Cited by 65
Ku, H.-C., Chen, W., & Su, M. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0665-3 · Cited by 65
“Exendin-4 suppresses LPS-induced mRNA expression of TNF-α, MCP1, and NFκB translocation to the nucleus in macrophage (Arakawa et al. 2010).”
BackgroundKuroki, T., Tanaka, R., Shimada, Y., Yamashiro, K., Ueno, Y., Shimura, H., Urabe, T., & Hattori, N. (2016) · Stroke · doi:10.1161/strokeaha.116.012934 · Cited by 60
Tang, S., Su, H., Zhang, Q., Tang, H., Wang, C., Zhou, Q., Wei, W., Zhu, H., & Wang, Y. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2578 · Cited by 65
Targeting QKI-7 in vivo restores endothelial cell function in diabetes
Yang, C., Eleftheriadou, M., Kelaini, S., Morrison, T. J., González, M. V., Caines, R., Edwards, N., Yacoub, A., Edgar, K. S., Moez, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17468-y · Cited by 62
Hullon, D., Subeh, G. K., Volkova, Y., Janiec, K., Trach, A., & Mnevets, R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02607-w · Cited by 59
“Similar effects were exerted by Exendin-4 [72].”
Ripa, R. S., Zobel, E. H., von Scholten, B. J., Jensen, J. K., Binderup, T., Diaz, L. J., Curovic, V. R., Hansen, T. W., Rossing, P., & Kjaer, A. (2021) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.120.012174 · Cited by 53
Helmstädter, J., Keppeler, K., Aust, F., Küster, L., Frenis, K., Filippou, K., Vujacic-Mirski, K., Tsohataridis, S., Kalinovic, S., Kröller-Schön, S., et al. (2021) · Antioxidants · doi:10.3390/antiox10081175 · Cited by 53
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
Vascular (dys)function in the failing heart
Liberale, L., Duncker, D. J., Hausenloy, D. J., Kraler, S. C., Bøtker, H. E., Podesser, B. K., Heusch, G., & Kleinbongard, P. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01163-w · Cited by 61
“Exposure of mouse macrophages to a GLP1 receptor agonist in vitro blunted the release of CCL2, IL-6 and TNF 206 , whereas continuous infusions of a GLP1 receptor agonist in hyperlipi-daemic mice in vivo attenuated monocyte adhesion and infiltration into atherosclerotic plaques 207 .”
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
“In rodents, exenatide treatment produced a significant reducion in carotid artery intima/media ratio (a surrogate marker of V disease) that was associated with a trend towards NF-kB eduction [131].”
BackgroundThe effect of liraglutide on endothelial function in patients with type 2 diabetes
Nandy, D., Johnson, C., Basu, R., Joyner, M., Brett, J., Svendsen, C. B., & Basu, A. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114547358 · Cited by 56
Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Turco, S. D., Gaggini, M., Daniele, G., Basta, G., Folli, F. B., Sicari, R., & Gastaldelli, A. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319130010 · Cited by 64
Elbassuoni, E. A., & Ahmed, R. F. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104583 · Cited by 54
Klingbeil, E. A., Cawthon, C. R., Kirkland, R. A., & Serre, C. B. D. L. (2019) · Nutrients · doi:10.3390/nu11112710 · Cited by 62
“As previously reported [62], a HF diet led to an increase in serum TNF-α which was reduced in HFRS rats (p = 0.07).”
BackgroundInfluentialDPP4 Activity, Hyperinsulinemia, and Atherosclerosis
Love, K. M., & Liu, Z. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab078 · Cited by 63
Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease
Panchapakesan, U., Mather, A., & Pollock, C. A. (2012) · Clinical Science · doi:10.1042/cs20120167 · Cited by 62
Hou, J., Manaenko, A., Hakon, J., Hansen-Schwartz, J., Tang, J., & Zhang, J. H. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.133 · Cited by 57
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
Bae, E. J. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0813-x · Cited by 62
“GLP-1R agonists as well as DPP-4 inhibitors reduce the atherosclerotic injury, such as lesion formation and monocyte or macrophage accumulation in the aorta of ApoE (–/–) mice (Arakawa et al. 2010; Matsubara et al. 2012; Vittone et al. 2012).”
BackgroundBruen, R., Curley, S., Kajani, S., Lynch, G., O’Reilly, M. E., Dillon, E. T., Brennan, E. P., Barry, M., Sheehan, S., McGillicuddy, F. C., et al. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.258343 · Cited by 52
“Indeed, increased circulating MCP-1 levels are related to increased risk of CVD and CVD mortality in patients with coronary artery disease (Ding et al., 2015).”
BackgroundInfluentialSalim, H. M., Fukuda, D., Higashikuni, Y., Tanaka, K., Hirata, Y., Yagi, S., Soeki, T., Shimabukuro, M., & Sata, M. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2015.08.011 · Cited by 56
Investigation of the haemodynamic effects of exenatide in healthy male subjects
Mendis, B., Simpson, E., MacDonald, I., & Mansell, P. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04214.x · Cited by 56
Li, W., Cui, M., Wei, Y., Kong, X., Tang, L., & Xu, D. (2012) · Cellular Physiology and Biochemistry · doi:10.1159/000341454 · Cited by 56
Han, L., Yu, Y., Sun, X., & Wang, B. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.04.001 · Cited by 60
“[11] Arakawa M, Mita T, Azuma K, Sajedi A, Smith KL, Parkinson JR, et al.”
BackgroundResultHirano, T., & Mori, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12446 · Cited by 55
“In U937 human monocytes, the active form of the incretin receptor agonists, Ex-4, GIP(1-42), and D-(Ala2) GIP, elicited cAMP generation, whereas the inactive form, GLP-1(9-36)amide and GIP (3-42), did not, suggesting that the incretins’ signal enters monocytes through classical incretin receptors.”
BackgroundNomoto, H., Miyoshi, H., Furumoto, T., Oba, K., Tsutsui, H., Inoue, A., Atsumi, T., Manda, N., Kurihara, Y., Aoki, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164255 · Cited by 58
Drug repurposing in kidney disease
Panchapakesan, U., & Pollock, C. A. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.026 · Cited by 57
Wan, S., & Sun, H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7347 · Cited by 55
Bułdak, Ł., Machnik, G., Bułdak, R. J., Łabuzek, K., Bołdys, A., & Okopień, B. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1277-8 · Cited by 55
Ohara, M., Nagaike, H., Goto, S., Fukase, A., Tanabe, Y., Tomoyasu, M., Yamamoto, T., Hayashi, T., Fukui, T., & Hirano, T. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.017 · Cited by 59
Zhou, T., Zhang, M., Zhao, L., Li, A., & Qin, X. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00093.2016 · Cited by 54
Jensen, J. K., Binderup, T., Grandjean, C. E., Bentsen, S., Ripa, R. S., & Kjaer, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.032 · Cited by 49
GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
Menghini, R., Casagrande, V., Rizza, S., & Federici, M. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02124-w · Cited by 47
“The data suggest that exendin-4 markedly reduced monocyte/macrophage accumulation in the vascular wall at least in part by suppressing the inflammatory response in macrophages through activation of the cAMP/PKA pathway [32].”
BackgroundIncretin actions beyond the pancreas: lessons from knockout mice
Yabe, D., & Seino, Y. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.013 · Cited by 57
“cytokine tumor necrosis factor a and monocyte chemoattractant protein-1from lipopolysaccharide-treated macrophages [25].”
BackgroundBeyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism
Ceccarelli, E., Guarino, E. G., Merlotti, D., Patti, A., Gennari, L., Nuti, R., & Dotta, F. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00073 · Cited by 51
Sudo, M., Li, Y., Hiro, T., Takayama, T., Mitsumata, M., Shiomi, M., Sugitani, M., Matsumoto, T., Hao, H., & Hirayama, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.920 · Cited by 56
Sandoval-Talamantes, A. K., Gómez-González, B. A., Uriarte-Mayorga, D. F., Martinez-Guzman, M. A., Hidalgo, K. A. W., & Alvarado‐Navarro, A. (2019) · Neuropeptides · doi:10.1016/j.npep.2019.102004 · Cited by 59
Hirata, Y., Kurobe, H., Nishio, C., Tanaka, K., Fukuda, D., Uematsu, E., Nishimoto, S., Soeki, T., Harada, N., Sakaue, H., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.057 · Cited by 58
Khound, R., Taher, J., Baker, C., Adeli, K., & Su, Q. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310251 · Cited by 51
Salim, H. M., Fukuda, D., Higashikuni, Y., Tanaka, K., Hirata, Y., Yagi, S., Soeki, T., Shimabukuro, M., & Sata, M. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.03.003 · Cited by 53
Zhan, J., Wang, Y., Wang, Y., Tang, Z.-Y., Tan, P., Huang, W., & Liu, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.086 · Cited by 51
Kaneto, H., Kimura, T., Shimoda, M., Obata, A., Sanada, J., Fushimi, Y., Nakanishi, S., Mune, T., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157917 · Cited by 51
Piccirillo, F., Mastroberardino, S., Nusca, A., Frau, L., Guarino, L., Napoli, N., Ussia, G. P., & Grigioni, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210164 · Cited by 58
“showed that exendin-4 reduced the accumulation of monocytes/macrophages in the vascular wall at least in part by suppressing the inflammatory response in macrophages through the activation of the cAMP/PKA pathway [68].”
BackgroundDragonieri, S., Portacci, A., Quaranta, V. N., Carratù, P., Lázár, Z., Carpagnano, G. E., & Bikov, A. (2024) · Diseases · doi:10.3390/diseases12090224 · Cited by 51
“In animal models, treatment with GLP-1RA has resulted in improvement in vascular inflammation and atherosclerosis [67].”
BackgroundLiraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice
Bisgaard, L. S., Bosteen, M. H., Fink, L. N., Sørensen, C. M., Rosendahl, A., Mogensen, C. K., Rasmussen, S. E., Rolin, B., Nielsen, L. B., & Pedersen, T. X. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168396 · Cited by 47
“Previously, mouse studies have shown that native GLP-1 and GLP-1 analogues attenuate atherosclerosis [15–17], and it has been hypothesized that this might be caused by decreased vascular inflammation [15, 17, 27, 28].”
BackgroundKamiya, M., Mizoguchi, F., & Yasuda, S. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13025 · Cited by 49
Antidiabetic Agents and Endothelial Dysfunction – Beyond Glucose Control
Eriksson, L., & Nyström, T. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12402 · Cited by 52
Nagayama, K., Kyotani, Y., Zhao, J., Ito, S., Ozawa, K., Bolstad, F. A., & Yoshizumi, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137960 · Cited by 48
“In addition, it was also reported that exendin-4 reduced the atherosclerotic lesion of apolipoprotein E knockout mice through the inhibition of monocyte adhesion to endothelial cells [27].”
Background
Metadata
- Authors
- Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H.
- Affiliations
- Juntendo University (JP)
- Corresponding author
- Mita, Tomoya
- Watada, Hirotaka
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-01-12
- Volume
- 59
- Issue
- 4
- Pages
- 1030-1037
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2844811
- OpenAlex
- W2142097676
- Cited by
- 548
- References
- 38
- Citations by year
- 2026: 31 · 2025: 25 · 2024: 34 · 2023: 27 · 2022: 37 · 2021: 33 · 2020: 27 · 2019: 25 · 2018: 36 · 2017: 32 · 2016: 41 · 2015: 46 · 2014: 36 · 2013: 35 · 2012: 43
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- exendin-4, GLP-1 receptor agonists, monocyte adhesion, endothelial cells, atherosclerosis, macrophage accumulation, ApoE-deficient mice, NF-κB, TNF-α, MCP-1, cAMP signaling, protein kinase A, CD11b, inflammation
- MeSH terms
- Exenatide, Animals, Aorta, Cell Adhesion, Endothelium, Vascular, Flow Cytometry, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Islets of Langerhans, Liver, Lung, Male, Mice, Inbred C57BL, Monocytes, Peptides, Venoms, Reverse Transcriptase Polymerase Chain Reaction, Atherosclerosis, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.